Suppr超能文献

在美国,关节疾病、抑制剂及其他并发症对重度甲型血友病男性患者健康相关生活质量的影响。

The effects of joint disease, inhibitors and other complications on health-related quality of life among males with severe haemophilia A in the United States.

作者信息

Soucie J M, Grosse S D, Siddiqi A-E-A, Byams V, Thierry J, Zack M M, Shapiro A, Duncan N

机构信息

Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA.

出版信息

Haemophilia. 2017 Jul;23(4):e287-e293. doi: 10.1111/hae.13275. Epub 2017 Jun 2.

Abstract

INTRODUCTION

Health-related quality of life (HRQoL) is reduced among persons with haemophilia. Little is known about how HRQoL varies with complications of haemophilia such as inhibitors and joint disease. Estimates of preference-based HRQoL measures are needed to model the cost-effectiveness of prevention strategies.

AIM

We examined the characteristics of a national sample of persons with severe haemophilia A for associations with two preference-based measures of HRQoL.

METHODS

We analysed utility weights converted from EuroQol 5 Dimensions (EQ-5D) and the Short Form 6 Dimensions (SF-6D) scores from 1859 males aged ≥14 years with severe haemophilia A treated at 135 US haemophilia treatment centres in 2005-2011. Bivariate and regression analyses examined age-group-specific associations of HRQoL with inhibitor status, overweight/obesity, number of bleeds, viral infections, indicators of liver and joint disease, and severe bleeding at the time of the first HRQoL measurement.

RESULTS

Overall mean HRQoL utility weight values were 0.71 using the SF-6D and 0.78 using the EQ-5D. All studied patient characteristics except for overweight/obesity were significantly associated with HRQoL in bivariate analyses. In a multivariate analysis, only joint disease was significantly associated with utility weights from both HRQoL measures and across all age groups. After adjustment for joint disease and other variables, the presence of an inhibitor was not significantly associated with HRQoL scores from either of the standardized assessment tools.

CONCLUSION

Clinically significant complications of haemophilia, especially joint disease, are strongly associated with HRQoL and should be accounted for in studies of preference-based health utilities for people with haemophilia.

摘要

引言

血友病患者的健康相关生活质量(HRQoL)有所降低。对于HRQoL如何随血友病并发症(如抑制剂和关节疾病)而变化,人们了解甚少。需要基于偏好的HRQoL测量估计值来模拟预防策略的成本效益。

目的

我们研究了一个全国性重度甲型血友病患者样本的特征,以探讨其与两种基于偏好的HRQoL测量方法之间的关联。

方法

我们分析了2005年至2011年在美国135个血友病治疗中心接受治疗的1859名年龄≥14岁的重度甲型血友病男性患者的欧洲五维健康量表(EQ-5D)和简短健康调查简表6维度(SF-6D)得分转换而来的效用权重。双变量和回归分析检验了HRQoL与抑制剂状态、超重/肥胖、出血次数、病毒感染、肝脏和关节疾病指标以及首次HRQoL测量时的严重出血之间的特定年龄组关联。

结果

使用SF-6D时,总体平均HRQoL效用权重值为0.71,使用EQ-5D时为0.78。在双变量分析中,除超重/肥胖外,所有研究的患者特征均与HRQoL显著相关。在多变量分析中,只有关节疾病在所有年龄组中均与两种HRQoL测量方法的效用权重显著相关。在调整关节疾病和其他变量后,抑制剂的存在与两种标准化评估工具的HRQoL得分均无显著关联。

结论

血友病的临床显著并发症,尤其是关节疾病,与HRQoL密切相关,在血友病患者基于偏好的健康效用研究中应予以考虑。

相似文献

2
Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.
Cochrane Database Syst Rev. 2024 Feb 27;2(2):CD014544. doi: 10.1002/14651858.CD014544.pub2.
4
No difference in quality of life between persons with severe haemophilia A and B.
Haemophilia. 2023 Jul;29(4):987-996. doi: 10.1111/hae.14759. Epub 2023 Feb 15.
10
Quality of life in haemophilia A: Hemophilia Utilization Group Study Va (HUGS-Va).
Haemophilia. 2012 Sep;18(5):699-707. doi: 10.1111/j.1365-2516.2012.02791.x. Epub 2012 Apr 17.

引用本文的文献

4
Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis.
Res Pract Thromb Haemost. 2023 Feb 8;7(2):100077. doi: 10.1016/j.rpth.2023.100077. eCollection 2023 Feb.
6
Investigating the Added Value of the EQ-5D-5L With Two Bolt-On Items in Patients With Hemophilia.
Front Med (Lausanne). 2021 Aug 5;8:707998. doi: 10.3389/fmed.2021.707998. eCollection 2021.

本文引用的文献

1
Interpreting important health-related quality of life change using the Haem-A-QoL.
Haemophilia. 2015 Sep;21(5):578-84. doi: 10.1111/hae.12642. Epub 2015 Mar 31.
2
Impact of inhibitors on hemophilia A mortality in the United States.
Am J Hematol. 2015 May;90(5):400-5. doi: 10.1002/ajh.23957. Epub 2015 Feb 5.
3
Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis.
Expert Rev Pharmacoecon Outcomes Res. 2015 Apr;15(2):267-83. doi: 10.1586/14737167.2015.1001372. Epub 2015 Jan 14.
7
Health care expenditures for Medicaid-covered males with haemophilia in the United States, 2008.
Haemophilia. 2012 Mar;18(2):276-83. doi: 10.1111/j.1365-2516.2011.02713.x. Epub 2011 Dec 21.
8
Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008.
Haemophilia. 2012 Mar;18(2):268-75. doi: 10.1111/j.1365-2516.2011.02692.x. Epub 2011 Dec 12.
10
The universal data collection surveillance system for rare bleeding disorders.
Am J Prev Med. 2010 Apr;38(4 Suppl):S475-81. doi: 10.1016/j.amepre.2009.12.023.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验